Advertisement

Japanese Journal of Ophthalmology

, Volume 62, Issue 2, pp 144–150 | Cite as

Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration

  • Hidetaka MatsumotoEmail author
  • Takashi Hiroe
  • Masahiro Morimoto
  • Kensuke Mimura
  • Arisa Ito
  • Hideo Akiyama
Clinical Investigation

Abstract

Purpose

To evaluate the efficacy of intravitreal aflibercept therapy using a treat-and-extend regimen on treatment-naïve pachychoroid neovasculopathy (PNV) and Type 1 neovascular age-related macular degeneration (AMD).

Methods

We retrospectively studied 42 eyes with PNV and 60 eyes with Type 1 neovascular AMD. We assessed best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and total number of injections over 2 years.

Results

The BCVA and CMT improvements during the 2-year treatment period did not differ significantly between PNV and AMD; however, CCT decreased significantly in PNV than in AMD (P<0.05). Management of PNV required significantly fewer injections than AMD during the 2-year period (P<0.05). There were no significant differences in BCVA, CMT and CCT changes between PNV with and without polypoidal lesions (28 vs. 14 eyes) during the 2 year period. Significantly fewer injections were needed for PNV with polypoidal lesions than for PNV without (P<0.01). There were no significant differences in BCVA, CMT and CCT changes, or in the number of injections during the 2-year treatment period, between AMD with and without polypoidal lesions (30 vs. 30 eyes).

Conclusion

Treat-and-extend regimen of intravitreal aflibercept injection may be equally effective in terms of improvement of BCVA and exudative changes both in eyes with PNV and those with Type 1 neovascular AMD requiring fewer injections for the former. Among eyes with PNV, those with polypoidal lesions needed fewer injections than those without polypoidal lesions.

Keywords

Pachychoroid neovasculopathy (PNV) Age-related macular degeneration (AMD) Type 1 neovascularization Anti-vascular endothelial growth factor (VEGF) Treat-and-extend 

Notes

Conflicts of interest

H. Matsumoto, None; T. Hiroe, None; M. Morimoto, None; K. Mimura, None; A. Ito, None; H. Akiyama, None.

References

  1. 1.
    Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015;35:1–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013;33:1659–72.CrossRefPubMedGoogle Scholar
  3. 3.
    Coscas G, Yamashiro K, Coscas F, De Benedetto U, Tsujikawa A, Miyake M, et al. Comparison of exudative age-related macular degeneration subtypes in Japanese and French patients: multicenter diagnosis with multimodal imaging. Am J Ophthalmol. 2014;158:309–18.CrossRefPubMedGoogle Scholar
  4. 4.
    Miyake M, Ooto S, Yamashiro K, Takahashi A, Yoshikawa M, Akagi-Kurashige Y, et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep. 2015;5:16204.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.CrossRefPubMedGoogle Scholar
  6. 6.
    Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.CrossRefPubMedGoogle Scholar
  7. 7.
    Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859–70.CrossRefPubMedGoogle Scholar
  8. 8.
    Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol. 2012;96:1157–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Steinbrook R. The price of sight—ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355:1409–12.CrossRefPubMedGoogle Scholar
  10. 10.
    Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43–58.CrossRefPubMedGoogle Scholar
  11. 11.
    Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679–80.CrossRefPubMedGoogle Scholar
  12. 12.
    Rayess N, Houston SK 3rd, Gupta OP, Ho AC, Regillo CD. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol. 2015;159:3–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Gass JD. Stereoscopic atlas of macular diseases. 4th ed. St. Louis: C.V. Mosby; 1997. p. 26–30.Google Scholar
  14. 14.
    Engelbert M, Zweifel SA, Freund KB. “Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina. 2009;29:1424–31.CrossRefPubMedGoogle Scholar
  15. 15.
    Matsumoto H, Sato T, Morimoto M, Mukai R, Takahashi M, Hiroe T, et al. Treat-and-extend regimen with aflibercept for retinal angiomatous proliferation. Retina. 2016;36:2282–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Yanai H. Statcel—the useful add-in software forms on excel. 4th ed. Tokyo: OMS; 2015.Google Scholar
  17. 17.
    Hata M, Yamashiro K, Ooto S, Oishi A, Tamura H, Miyata M, et al. Intraocular vascular endothelial growth factor levels in pachychoroid neovasculopathy and neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58:292–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141:456–62.CrossRefPubMedGoogle Scholar
  19. 19.
    Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology. 2012;119:1621–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, et al. Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results. Ophthalmology. 2016;123:617–24.CrossRefPubMedGoogle Scholar
  21. 21.
    Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274:H1054–8.PubMedGoogle Scholar
  22. 22.
    Kim YK, Ryoo NK, Woo SJ, Park KH. Choroidal thickness changes after photodynamic therapy and recurrence of chronic central serous chorioretinopathy. Am J Ophthalmol. 2015;160:72–84.CrossRefPubMedGoogle Scholar
  23. 23.
    Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2011;151:594–603.CrossRefPubMedGoogle Scholar
  24. 24.
    Sato T, Kishi S, Matsumoto H, Mukai R. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;149:947–54.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2018

Authors and Affiliations

  • Hidetaka Matsumoto
    • 1
    Email author
  • Takashi Hiroe
    • 1
  • Masahiro Morimoto
    • 1
  • Kensuke Mimura
    • 1
  • Arisa Ito
    • 1
  • Hideo Akiyama
    • 1
  1. 1.Department of OphthalmologyGunma University, School of MedicineMaebashiJapan

Personalised recommendations